Status:
COMPLETED
Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer
Lead Sponsor:
Instituto Brasileiro de Controle do Cancer
Conditions:
Nausea Post Chemotherapy
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This is a longitudinal, one arm, prospective phase II study, designed to evaluate the efficacy of Olanzapine Netupitant and Palonosetron in the controll of nausea and vomiting induced by highly emetog...
Detailed Description
The population of the study is women diagnosed with breast cancer, who will start chemotherapy (Doxorubicine and Cyclophosfamide). We will evaluate the control of nausea and vomiting in the first cycl...
Eligibility Criteria
Inclusion
- Breast cancer hitologically confirmed
- 18 Years and older (Adult, Older Adult)
- Patients about to start use of Doxorubicine 60mg/m2 + Cyclophosfamide 600mg/m2
- No previous chemotherapy for breast cancer
Exclusion
- Patients not capable of completing the questionnaire
- Patients with other condition that could cause nausea and emesis
- Use of opioids
- Use of antipsychotic medications
- Patients not capable of taking medications orally
Key Trial Info
Start Date :
December 17 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 17 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04669132
Start Date
December 17 2020
End Date
January 17 2022
Last Update
February 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IBCC Oncologia
São Paulo, Brazil, 03102002